Large pharmaceutical firms are increasingly upset at the deal they agreed with the British government on drug pricing, the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).
Negotiated in 2019, VPAS caps the growth of branded medicine spending on the part of the NHS, the UK’s national healthcare provider, at a rate of 2% per year.
Since the deal was agreed, rising UK healthcare demands have driven up drug usage and repayment rates to a much higher-than-expected level.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze